BRIEF: WuXi XDC profit jumps on rising revenue, improving margins
Pharmaceutical contract services provider WuXi XDC Cayman Inc. (2268.HK) said on Wednesday it expects to report its annual revenue rose 45% in 2025, as its gross profit surged over 70% on improving margin profiles across its various products and services, and its cost containment measures bore fruit.
Despite headwinds from currency and interest rate fluctuations, the company said it expects to report its net profit for the year rose 38% from 2024. Based on its 2024 net profit of 1.07 billion yuan ($153 million), that means the company expects to report a 2025 profit of about 1.48 billion yuan.
Separately, WuXi XDC announced a general offer to acquire BioDlink (1875.HK) for HK$4 per share — representing a 60% premium over BioDlink ‘s last price of HK$2.50 before trading in its shares was suspended. The transaction, valued at approximately HK$2.79 billion ($358 million), will be funded using internal resources. WuXi XDC emphasized it “will not raise the offer price.”
Shares of WuXi XDC fell 3.8% on Thursday, but the stock is up 20% over the last 52 weeks. Shares of BioDlink rose 67.6% to close at HK$4.19.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, click here
